[Form 4] Outset Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Marc Nash, Outset Medical's EVP, Research & Development, Operations and Services, received a grant of 5,617 restricted stock units (RSUs) on 08/25/2025. Each RSU converts to one share of common stock at no purchase price ($0.0). Following the grant, the reporting person beneficially owned 48,515 shares. The RSUs vest 33.33% on August 15, 2026, with the remaining 66.67% vesting in equal quarterly installments over the subsequent two years on each February 15, May 15, August 15 and November 15, contingent on continuous service through each vesting date.

Insights

Compensation Analyst

TL;DR: Executive equity award granted with multi-year quarterly vesting to retain senior R&D/operations leadership.

The filing documents an equity-based compensation award of 5,617 RSUs to the company's EVP of R&D and Operations. The grant carries a zero exercise price and a staggered vesting schedule starting August 15, 2026, with quarterly vesting thereafter for two years, conditioned on continuous service. This structure is typical for retention and alignment of senior management incentives with shareholders, and the reported post-grant beneficial ownership is 48,515 shares. The disclosure is routine and does not indicate any accelerated vesting, transfers, or cash consideration.

Corporate Governance Expert

TL;DR: Routine insider equity grant disclosed under Section 16; vesting terms and ownership clearly reported.

The Form 4 timely reports an internal equity grant to a named officer, including the full vesting timetable and the condition of continuous service. The document is a standard compliance disclosure under Section 16 and provides the required details: grant date (08/25/2025), number of RSUs (5,617), and subsequent total beneficial ownership (48,515). No derivative transactions, dispositions, or amendments are reported. The filing appears complete for its purpose.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nash Marc

(Last) (First) (Middle)

3052 ORCHARD DRIVE

(Street)

SAN JOSE CA 95134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, R&D, Operations and Serv.

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		A		5,617(1)	A	$0.0	48,515	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSU") granted to the reporting person on August 25, 2025. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest 33.33% on August 15, 2026, and the remaining 66.67% shall vest in equal installments over the course of the following two years on a quarterly basis on each February 15th, May 15th, August 15th and November 15th, subject to the reporting person's continuous service through the applicable vesting date.

	By: John L Brottem For: Marc Nash	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Marc Nash receive according to the Form 4 for OM?

The Form 4 reports a grant of 5,617 restricted stock units (RSUs) to Marc Nash on 08/25/2025.

What is the vesting schedule for the RSUs granted to Marc Nash?

The RSUs vest 33.33% on August 15, 2026, with the remaining 66.67% vesting in equal quarterly installments over the next two years on each Feb 15, May 15, Aug 15 and Nov 15, subject to continuous service.

What is Marc Nash's beneficial ownership after the reported transaction?

Following the reported grant, the filing shows beneficial ownership of 48,515 shares.

Was there any cash paid for the RSUs?

No. The Form 4 shows a price of $0.0, indicating the RSUs were granted without cash purchase price.

Does the Form 4 report any derivative or other transactions for Marc Nash?

No derivative securities or other transactions are reported in Table II; only the RSU grant is disclosed in Table I.